Current perspectives of insulin resistance and polycystic ovary syndrome

Diabetic Medicine

Volumn 28, Issue 12, 2011, Pages 1445-1454

  Pauli, J M ^a   Raja Khan, N ^a   Wu, X ^b   Legro, R S ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b HEILONGJIANG UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Androgens; Cardiovascular disease; Diabetes; Infertility; Pregnancy

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; TRIACYLGLYCEROL; TROGLITAZONE;

ADIPOSE TISSUE; ADRENAL GLAND; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DISEASE ASSOCIATION; DYSLIPIDEMIA; ENDOMETRIUM; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; FEMALE; FEMALE INFERTILITY; FIBROBLAST; HUMAN; HYPERANDROGENISM; INSULIN BINDING; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIFESTYLE MODIFICATION; LIVER; MATERNAL DIABETES MELLITUS; MOLECULAR MECHANICS; OVARY POLYCYSTIC DISEASE; PREGNANCY; PREGNANCY COMPLICATION; REVIEW; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; THECA CELL; TRIACYLGLYCEROL BLOOD LEVEL;

ADIPOSE TISSUE; CARDIOVASCULAR DISEASES; FEMALE; FERTILITY; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; METFORMIN; MUSCLE, SKELETAL; POLYCYSTIC OVARY SYNDROME; PREGNANCY; RISK FACTORS; SIGNAL TRANSDUCTION;

EID: 81355151407     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2011.03460.x     Document Type: Review

References (109)

1. Virkamaki A, Ueki K, Kahn CR. Protein-protein interaction in insulin signaling and the molecular mechanisms of insulin resistance. J Clin Invest 1999; 103: 931-943.
2. Mannerås-Holm L, Leonhardt H, Kullberg J, Jennische E, Odén A, Holm G et al. Adipose tissue has aberrant morphology and function in PCOS: enlarged adipocytes and low serum adiponectin, but not circulating sex steroids, are strongly associated with insulin resistance. J Clin Endocrinol Metab 2011; 96: E304-E311.
3. Ciaraldi TP, Aroda V, Mudaliar S, Chang RJ, Henry RR. Polycystic ovary syndrome is associated with tissue-specific differences in insulin resistance. J Clin Endocrinol Metab 2009; 94: 157-163.
4. Nada SE, Thompson RC, Padmanabhan V. Developmental programming: differential effects of prenatal testosterone excess on insulin target tissues. Endocrinology 2010; 151: 5165-5173.
5. Chang W, Goodarzi MO, Williams H, Magoffin DA, Pall M, Azziz R. Adipocytes from women with polycystic ovary syndrome demonstrate altered phosphorylation and activity of glycogen synthase kinase 3. Fertil Steril 2008; 90: 2291-2297.
6. Corbould A, Kim YB, Youngren JF, Pender C, Kahn BB, Lee A et al. Insulin resistance in the skeletal muscle of women with PCOS involves intrinsic and acquired defects in insulin signaling. Am J Physiol Endocrinol Metab 2005; 288: E1047-E1054.
7. Ciaraldi TP, Morales AJ, Hickman MG, Odom-Ford R, Olefsky JM, Yen SS. Cellular insulin resistance in adipocytes from obese polycystic ovary syndrome subjects involves adenosine modulation of insulin sensitivity. J Clin Endocrinol Metab 1997; 82: 1421-1425.
8. Dunaif A, Xia JR, Book CB, Schenker E, Tang Z. Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle. J Clin Inves 1995; 96: 801-810.
9. Højlund K, Glintborg D, Andersen NR, Birk JB, Treebak JT, Frøsig C et al. Impaired insulin-stimulated phosphorylation of Akt and AS160 in skeletal muscle of women with polycystic ovary syndrome is reversed by pioglitazone treatment. Diabetes 2008; 57: 357-366.
10. Corbould A, Zhao H, Mirzoeva S, Aird F, Dunaif A. Enhanced mitogenic signaling in skeletal muscle of women with polycystic ovary syndrome. Diabetes 2006; 55: 751-759.
11. Kubota N, Kubota T, Itoh S, Kumaqai H, Kozono H, Takamoto I et al. Dynamic functional relay between insulin receptor substrate1 and 2 in hepatic insulin signaling during fasting and feeding. Cell Metab 2008; 8: 49-64.
12. Nestler JE, Powers LP, Matt DW, Steingold KA, Plymate SR, Rittmaster RS et al. A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab 1991; 72: 83-89.
13. Baranova A, Tran TP, Birerdinc A, Younossi ZM. Systematic review: association of polycystic ovary syndrome with metabolic syndrome and non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2011; 33: 801-814.
14. Dunaif A, Wu X, Lee A, Diamanti-Kandarakis E. Defects in insulin receptor signaling in vivo in the polycystic ovary syndrome. Am J Physiol Endocrinol Metab 2001; 281: E392-E399.
15. Li M, Youngren JF, Dunaif A, Goldfine ID, Maddux BA, Zhang BB et al. Decreased insulin receptor (IR) autophosphorylation in fibroblasts from patients with PCOS: effects of serine kinase inhibitors and IR activators. J Clin Endocrinol Metab 2002; 87: 4088-4093.
16. Venkatesan AM, Dunaif A, Corbould A. Insulin resistance in polycystic ovary syndrome: progress and paradoxes. Recent Prog Horm Res 2001; 56: 295-308.
17. Rice S, Christoforidis N, Gadd C, Nikolaou D, Seyani L, Donaldson A. Impaired insulin-dependent glucose metabolism in granulosa-lutein cells from anovulatory women with polycystic ovaries. Hum Reprod 2005; 20: 373-381.
18. Wu XK, Zhou SY, Liu JX, Pollanen P, Sallinen K, Makinen M et al. Selective ovary resistance to insulin signaling in women with polycystic ovary syndrome. Fertil Steril 2003; 80: 954-965.
19. Chakrabarty S, Nagamani M. Peripubertal hyperinsulinemia upregulates phosphatidyli-nositol 3-kinase/akt pathway in rat ovaries. Reprod Sci 2008; 15: 274-284.
20. Qu J, Wang Y, Wu X, Gao L, Hou L, Erkkola R. Insulin resistance directly contributes to androgenic potential within ovarian theca cells. Fertil Steril 2009; 91: S1990-S1997.
21. Zhao L, Li W, Han F, Hou L, Baillargeon JP, Kuang H et al. Berberine reduces insulin resistance induced by dexamethasone in theca cells in vitro. Fertil Steril 2011; 95: 461-463.
22. Munir I, Yen HW, Geller DH, Torbati D, Bierden RM, Weitsman SR et al. Insulin augmentation of 17a-hydroxylase activity is mediated by phosphatidyl inoaitel 3-kiIlase but not extracellular signal-regulated kinase-1/2 in human ovarian theca cells. Endocrinology 2004; 145: 175-183.
23. Yan M, Wang J, Wu X, Hou L, Kuang H, Wang Y. Induction of insulin resistance by phosphatidylinositol-3-kinase inhibitor in porcine granulosa cells. Fertil Steril 2009; 92: 2119-2121.
24. Iwase A, Goto M, Harata T, Takigawa S, Nakahara T, Suzuki K et al. Insulin attenuates the insulin-like growth factor-I (IGF-I)-Akt pathway, not IGF-I-extracellularly regulated kinase pathway, in luteinized granulosa cells with an increase in PTEN. J Clin Endocrinol Metab 2009; 94: 2184-2191.
25. Sonntag B, Gotte M, Wulfing P, Schüring AN, Kiesel L, Greb RR. Metformin alters insulin signaling and viability of human granulosa cells. Fertil Steril 2005; 84: S1173-S1179.
26. Rosas C, Gabler F, Vantman D, Romero C, Vega M. Levels of Rabs and WAVE family proteins associated with translocation of GLUT4 to the cell surface in endometria from hyperinsulinemic PCOS women. Hum Reprod 2010; 25: 2870-2877.
27. Hardiman P, Pillay OC, Atiomo W. Polycystic ovary syndrome and endometrial carcinoma. Lancet 2003; 361: 1810-1812.
28. Villavicencio A, Aguilar G, Argüello G, Dunner C, Gabler F, Soto E et al. The effect of overweight and obesity on proliferation and activation of AKT and ERK in human endometria. Gynecol Oncol 2010; 117: 96-102.
29. Shen ZQ, Zhu HT, Lin JF. Reverse of progestin-resistant atypical endometrial hyperplasia by metformin and oral contraceptives. Obstet Gynecol 2008; 112: 465-467.
30. Fornes R, Ormazabal P, Rosas C, Gabler F, Vantman D, Romero C et al. Changes in the expression of insulin signaling pathway molecules in endometria from polycystic ovary syndrome women with or without hyperinsulinemia. Mol Med 2010; 16: 129-136.
31. Mioni R, Chiarelli S, Xamin N, Zuliani L, Granzotto M, Mozzanega B et al. Evidence for the presence of glucose transporter4 in the endometrium and its regulation in polycystic ovary syndrome patients. J Clin Endocrinol Metab 2004; 89: 4089-4096.
32. Villavicencio A, Bacallao K, Gabler F, Fuentes A, Albornoz J, Casals A et al. Deregulation of tissue homeostasis in endometria from patients with polycystic ovarian syndrome with and without endometrial hyperplasia. Gynecol Oncol 2007; 104: 290-295.
33. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997; 18: 774-800.
34. Maliqueo M, Sir-Petermann T, Pérez V, Echiburu B, deGuevara AL, Galvez C et al. Adrenal function during childhood and puberty in daughters of women with polycystic ovary syndrome. J Clin Endocrinol Metab 2009; 94: 3282-3288.
35. Guido M, Romualdi D, Suriano R, Giuliani M, Costantini B, Apa R et al. Effect of pioglitazone treatment on the adrenal androgen response to corticotrophin in obese patients with polycystic ovary syndrome. Hum Reprod 2004; 19: 534-539.
36. Kumar A, Woods KS, Bartolucci AA, Azziz R. Prevalence of adrenal androgen excess in patients with the polycystic ovary syndrome (PCOS). J Clin Endocrinol (Oxf) 2005; 62: 644-649.
37. Arslanian SA, Lewy V, Danadian K, Saad R. Metformin therapy in obese adolescents with polycystic ovary syndrome and impaired glucose tolerance: amelioration of exaggerated adrenal response to adrenocorticotropin with reduction of insulinemia/insulin resistance. J Clin Endocrinol Metab 2002; 87: 1555-1559.
38. Montagnani M, Golovchenko I, Kim I, Koh GY, Goalstone ML, Mundhekar AN et al. Inhibition of phosphatidylinositol 3-kinase enhances mitogenic actions of insulin in endothelial cells. J Biol Chem 2002; 277: 1794-1799.
39. Macko AR, Beneze AN, Teachey MK, Henriksen EJ. Roles of insulin signaling and p38 MAPK in the activation by lithium of glucose transport in insulin-resistant rat skeletal muscle. Arch Physiol Biochem 2008; 114: 33l-339.
40. Brettenthaler N, De Geyter C, Huber PR, Keller U. Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004; 89: 3835-3840.
41. Franks S, Stark J, Hardy K. Follicle dynamics and anovulation in polycystic ovary syndrome. Hum Reprod Update 2008; 14: 367-378.
42. Kim JY, Song H, Kim H, Kang HJ, Jun JH, Hong SR et al. Transcriptional profiling with a pathway-oriented analysis identifies dysregulated molecular phenotypes in the endometrium of patients with polycystic ovary syndrome. J Clin Endocrinol Metab 2009; 94: 1416-1426.
43. Puurunen J, Piltonen T, Jaakkola P, Ruokonen A, Morin-Papunen L, Tapanainen JS. Adrenal androgen production capacity remains high up to menopause in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2009; 94: 1973-1978.
44. Farah-Eways L, Reyna R, Knochenhauer ES, Bartolucci AA, Azziz R. Glucose action and adrenocortical biosynthesis in women with polycystic ovary syndrome. Fertil Steril 2004; 81: 120-125.
45. Nestler JE. Metformin for the treatment of the polycystic ovary syndrome. N Engl J Med 2008; 358: 47-54.
46. Escobar-Morreale HF, Botella-Carretero JI, Alvarez-Blasco F, Sancho J, San Millan JL. The polycystic ovary syndrome associated with morbid obesity may resolve after weight loss induced by bariatric surgery. J Clin Endocrinol Metab 2005; 90: 6364-6369.
47. Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Consensus on infertility treatment related to polycystic ovary syndrome. Fertil Steril 2008; 89: 505-522.
48. Harrison CL, Lombard CB, Moran LJ, Teede HJ. Exercise therapy in polycystic ovary syndrome: a systematic review. Hum Reprod Update 2011; 17: 171-183.
49. Moran LJ, Hutchison SK, Norman RJ, Teede HJ. Lifestyle changes in women with polycystic ovary syndrome. Cochrane Database Syst Rev 2011; 7: CD007506.
50. Thomson RL, Buckley JD, Moran LJ, Noakes M, Clifton PM, Norman RJ et al. Comparison of aerobic exercise capacity and muscle strength in overweight women with and without polycystic ovary syndrome. BJOG 2009; 116: 1242-1250.
51. Ladson G, Dodson WC, Sweet SD, Archibong AE, Kunselman AR, Demers LM et al. The effects of metformin with lifestyle therapy in polycystic ovary syndrome: a randomized double-blind study. Fertil Steril 2011; 95: 1059-1066, e1-e7.
52. Azziz R, Ehrmann D, Legro RS, Whitcomb RW, Hanley R, Fereshetian AG et al. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. J Clin Endocrinol Metab 2001; 86: 1626-1632.
53. Azziz R, Ehrmann DA, Legro RS, Fereshetian AG, O'Keefe M, Ghazzi MN. Troglitazone decreases adrenal androgen levels in women with polycystic ovary syndrome. Fertil Steril 2003; 79: 932-937.
54. Nestler JE, Jakubowicz DJ, Reamer P, Gunn RD, Allan G. Ovulatory and metabolic effects of d-chiro-inositol in the polycystic ovary syndrome. N Engl J Med 1999; 340: 1314-1320.
55. Elkind-Hirsch K, Marrioneaux O, Bhushan M, Vernor D, Bhushan R. Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metab 2008; 93: 2670-2678.
56. Ibanez L, Lopez-Bermejo A, Diaz M, Marcos MV, de Zegher F. Metformin treatment for four years to reduce total and visceral fat in low birth weight girls with precocious pubarche. J Clin Endocrinol Metab 2008; 93: 1841-1845.
57. Crowther CA, Hiller JE, Moss JR, McPhee AJ, Jeffries WS, Robinson JS. Effect of treatment of gestational diabetes mellitus on pregnancy outcomes. N Engl J Med 2005; 352: 2477-2486.
58. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA et al. Reduction in the incidence of type2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403.
59. Legro RS, Barnhart HX, Schlaff WD, Carr BR, Diamond MP, Carson SA et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med 2007; 356: 551-566.
60. Moll E, van der Veen F, van Wely M. The role of metformin in polycystic ovary syndrome: a systematic review. Hum Reprod Update 2007; 13: 527-537.
61. Palomba S, Falbo A, Orio F Jr, Zullo F. Effect of preconceptional metformin on abortion risk in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. Fertil Steril 2009; 92: 1646-1658.
62. Tang T, Lord JM, Norman RJ, Yasmin E, Balen AH. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, d-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev 2010; Jan 20 (1): CD003053.
63. Costello M, Shrestha B, Eden J, Sjoblom P, Johnson N. Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome. Cochrane Database Syst Rev 2007; Jan 24 (1): CD005552.
64. Tang T, Glanville J, Hayden CJ, White D, Barth JH, Balen AH. Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study. Hum Reprod 2006; 21: 80-89.
65. Hoeger K, Davidson K, Kochman L, Cherry T, Kopin L, Guzick DS. The impact of metformin, oral contraceptives and lifestyle modification, on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials. J Clin Endocrinol Metab 2008; 93: 4299-4306.
66. Ladson G, Dodson WC, Sweet SD, Archibong AE, Kunselman AR, Demers LM et al. Effects of metformin in adolescents with polycystic ovary syndrome undertaking lifestyle therapy: a pilot randomized double-blind study. Fertil Steril 2011; 95: 2595-2598, e6.
67. Butte NF. Carbohydrate and lipid metabolism in pregnancy: normal compared with gestational diabetes mellitus. Am J Clin Nutr 2000; 71: 1256S-1261S.
68. American College of Obstetricians and Gynecologists (ACOG). Gestational diabetes. ACOG Practice Bulletin No.30. Obstet Gynecol 2001; 98: 525-538.
69. Getahun D, Nath C, Ananth CV, Chavez MR, Smullian JC. Gestational diabetes in the United States: temporal trends 1989 through 2004. Am J Obstet Gynecol 2008; 198: 525, e1-e5.
70. Catalano PM, Kirwan JP, Haugel-de Mouzon S, King J. Gestational diabetes and insulin resistance: role in short- and long-term implications for mother and fetus. J Nutr 2003; 133: 1674S-1683S.
71. Altieri P, Gamineri A, Prontera O, Cionci G, Franchina M, Pasquali R. Maternal polycystic ovary syndrome may be associated with adverse pregnancy outcomes. Eur J Obstet Gynecol Reprod Bio 2010; 149: 31-36.
72. Lo JC, Feigenbaum SL, Escobar GJ, Yang J, Crites YM, Ferrara A. Increased prevalence of gestational diabetes mellitus among women with diagnosed polycystic ovary syndrome: a population-based study. Diabetes Care 2006; 29: 1915-1917.
73. Legro RS, Castracane VD, Kauffman RP. Detecting insulin resistance in polycystic ovary syndrome: purposes and pitfalls. Obstet Gynecol Surv 2004; 59: 141-154.
74. Haakova L, Cibula D, Rezabek K, Hill M, Fanta M, Zivny J. Pregnancy outcome in women with PCOS and in controls matched by age and weight. Hum Reprod 2003; 18: 1438-1441.
75. Mikola M, Hiilesmaa V, Halttunen M, Suhonen L, Tiitinen A. Obstetric outcome in women with polycystic ovarian syndrome. Hum Reprod 2001; 16: 226-229.
76. Ott J, Kurz C, Nouri K, Wirth S, Vytiska-Binstorfer E, Huber JC et al. Pregnancy outcome in women with polycystic ovary syndrome comparing the effects of laparoscopic ovarian drilling and clomiphene citrate stimulation in women pre-treated with metformin: a retrospective study. Reprod Biol Endocrinol 2010; 8: 45.
77. Boomsma CM, Eijkemans MJC, Huges EG, Visser GHA, Fauser BCJM, Mackon NS. A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome. Hum Reprod Update 2006; 12: 673-683.
78. Radon PA, Mcmahon MJ, Meyer WR. Impaired glucose tolerance in pregnant women with polycystic ovary syndrome. Obstet Gynecol 1999; 94: 194-197.
79. Lanzone A, Fulghesu AM, Cucinelli F, Guido M, Pavone V, Caruso A et al. Preconceptional and gestational evaluation of insulin secretion in patients with polycystic ovary syndrome. Hum Reprod 1996; 11: 2382-2386.
80. Homburg R. Pregnancy complications in PCOS. Best Pract Res Clin Endocrinol Metab 2006; 20: 281-292.
81. Thatcher SS, Jackson EM. Pregnancy outcome in infertile patients with polycystic ovary syndrome who were treated with metformin. Fertil Steril 2006; 85: 1002-1009.
82. Boomsma CM, Fauser BC, Macklon NS. Pregnancy complications in women with polycystic ovary syndrome. Semin Reprod Med 2008; 26: 72-84.
83. Iavazzo C, Vitoratos N. Polycystic ovarian syndrome and pregnancy outcome. Arch Gynecol Obstet 2010; 282: 235-239.
84. Barker DJP, Osmond C, Simmonds SJ, Wield GA. The relation of small head circumference and thinness at birth to death from cardiovascular disease in adult life. Br Med J 1993; 306: 422-426.
85. Barker, DJ. Early growth and cardiovascular disease. Arch Dis Child 1999; 80: 305-310.
86. Barker DJ, Winter PD, Osmond C, Margetts B, Simmonds SJ. Weight in infancy and death from ischaemic heart disease. Lancet 1989; 2: 577-580.
87. Hales CN, Barker DJ, Clark PM, Cox V, Fall C, Osmond C et al. Fetal and infant growth and impaired glucose tolerance at age 64. Br Med J 1991; 303: 1019-1022.
88. De Boo HA, Harding JE. The developmental origins of adult disease (Barker) hypothesis. Aust N Z J Obstet Gynaecol 2006; 46: 4-14.
89. Fall C, Stein CE, Kumaran K, Cox V, Osmond C, Barker DJ et al. Size at birth, maternal weight, and non-insulin dependent diabetes in South India. Diabet Med 1998; 15: 220-227.
90. Legro RS, Castracane VD, Kauffman RP. Detecting insulin resistance in polycystic ovary syndrome: purposes and pitfalls. Obstet Gynecol Surv 2004; 59: 141-154.
91. Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989; 38: 1165-1174.
92. Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 1999; 84: 165-169.
93. Ehrmann DA, Kasza K, Azziz R, Legro RS, Ghazzi MN. Effects of race and family history of type2 diabetes on metabolic status of women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005; 90: 66-71.
94. Barrett-Connor E, Giardina EG, Gitt AK, Gudat U, Steinberg HO, Tschoepe D. Women and heart disease: the role of diabetes and hyperglycemia. Arch Inter Med 2004; 164: 934-942.
95. Moran LJ, Misso ML, Wild RA, Norman RJ. Impaired glucose tolerance, type2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update 2010; 16: 347-363.
96. Diamanti-Kandarakis E, Papavassiliou AG, Kandarakis SA, Chrousos GP. Pathophysiology and types of dyslipidemia in PCOS. Trends Endocrinol Metab 2007; 18: 280-285.
97. Wild RA, Rizzo M, Clifton S, Carmina E. Lipid levels in polycystic ovary syndrome: systematic review and meta-analysis. Fertil Steril 2011; 95: 1073-1079, e1-e11.
98. Wild RA, Alaupovic P, Parker IJ. Lipid and apolipoprotein abnormalities in hirsute women. I. The association with insulin resistance. Am J Obstet Gynecol 1992; 166: 1191-1196.
99. Goodarzi MO, Erickson S, Port SC, Jennrich RI, Korenman SG. Relative impact of insulin resistance and obesity on cardiovascular risk factors in polycystic ovary syndrome. Metabolism 2003; 52: 713-719.
100. Cascella T, Palomba S, Tauchmanova L, Manguso F, Di Biase S, Labella D et al. Serum aldosterone concentration and cardiovascular risk in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 2006; 91: 4395-4400.
101. Diamanti-Kandarakis E, Economou FN, Livadas S, Tantalaki E, Piperi C, Papavassiliou AG et al. Hyperreninemia characterizing women with polycystic ovary syndrome improves after metformin therapy. Kidney Blood Press Res 2009; 32: 24-31.
102. Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities-the role of insulin resistance and the sympathoadrenal system. N Engl J Med 1996; 334: 374-381.
103. Sverrisdottir YB, Mogren T, Kataoka J, Janson PO, Stener-Victorin E. Is polycystic ovary syndrome associated with high sympathetic nerve activity and size at birth? Am J Physiol Endocrinol Metab 2008; 294: E576-E581.
104. Westerbacka J, Wilkinson I, Cockcroft J, Utriainen T, Vehkavaara S, Yki-Jarvinen H. Diminished wave reflection in the aorta. A novel physiological action of insulin on large blood vessels. Hypertension 1999; 33: 1118-1122.
105. Holte J, Gennarelli G, Berne C, Bergh T, Lithell H. Elevated ambulatory daytime blood pressure in women with polycystic ovary syndrome: a sign of a pre-hypertensive state? Hum Reprod 1996; 11: 23-28.
106. Sampson M, Kong C, Patel A, Unwin R, Jacobs HS. Ambulatory blood pressure profiles and plasminogen activator inhibitor (PAI-1) activity in lean women with and without the polycystic ovary syndrome. Clin Endocrinol 1996; 45: 623-629.
107. Meyer C, McGrath BP, Teede HJ. Overweight women with polycystic ovary syndrome have evidence of subclinical cardiovascular disease. J Clin Endocrinol Metab 2005; 90: 5711-5716.
108. Talbott EO, Guzick DS, Sutton-Tyrrell K, McHugh-Pemu KP, Zborowski JV, Remsberg KE et al. Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women. Arterioscler Thromb Vasc Biol 2000; 20: 2414-2421.
109. Talbott EO, Zborowski JV, Rager JR, Boudreaux MY, Edmundowicz DA, Guzick DS. Evidence for an association between metabolic cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004; 89: 5454-5461.